M. C. Williams, J. T. Murchison, L. D. Edwards, A. Agusti, P. Bakke, P. M. Calverley, B. Celli, H. O. Coxson, C. Crim, D. A. Lomas, B. E. Miller, S. Rennard, E. K. Silverman, R. Tal-Singer, J. Vestbo, E. Wouters, J. C. Yates, E. J. van Beek, D. E. Newby, W. MacNee


1468-3296 (Electronic) 0040-6376 (Linking)

Publication year




Periodical Number






Author Address

University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK. Royal Infirmary of Edinburgh, Edinburgh, UK. GlaxoSmithKline, Research Triangle Park, North Carolina, USA. Thorax Institute, Hospital Clinic, Universitat de Barcelona; CIBER Enfermedades Respiratorias (CIBERES), FISIB, Mallorca, Spain. University of Bergen, Bergen, Norway. Department of Respiratory Medicine, University Hospital Aintree, Liverpool, UK. Department of Respiratory Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. University of British Columbia, Vancouver, British Columbia, Canada. Department of Medicine, University of Cambridge, Cambridge, UK. GlaxoSmithKline, King of Prussia, Pennsylvania, USA. University of Nebraska Medical Center, Omaha, Nebraska, USA. Department of Respiratory Medicine, Odense University & University of Southern Denmark, Denmark/University of Manchester, Academic Health Science Centre, Manchester, UK. Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands. Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, UK. Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.

Full version

BACKGROUND: Coronary artery calcification is pathognomonic of coronary artery disease (CAD). Whether CAD in patients with COPD is linked to lung function, functional capacity and/or clinically relevant outcomes is unknown. The objective was to assess the association between CAD and disease severity, functional capacity and outcomes in patients with COPD. METHODS: Coronary artery calcium score (CACS; Agatston score) was measured using chest CT in patients with COPD, smokers with normal spirometry and non-smokers from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. RESULTS: CACS was measured in 942 subjects: 672 with COPD (mean age+/-SD, 63+/-7 years; FEV1 49+/-16% predicted), 199 smokers with normal spirometry (54+/-9 years; FEV1 110+/-12% predicted) and 71 non-smokers (55+/-9 years; FEV1 114+/-14% predicted). CACS was higher in patients with COPD than smokers or non-smokers (median (IQR), 128 (492) vs 0 (75) vs 0 (3) Agatston units (AU), p<0.001). In patients with COPD, CACS correlated with age, pack-years, 6 min walking distance, modified Medical Research Council Dyspnoea score and circulating levels of interleukin (IL)-6, IL-8, Clara Cell protein 16, surfactant protein D and peripheral blood neutrophil count, but not with emphysema, exacerbation frequency, % predicted FEV1 or decline in FEV1. CACS was higher in patients with COPD who died than in those who survived until 3-year follow-up (CACS 406 vs 103 AU, p<0.001), and was associated with mortality in a Cox proportional hazards model (p=0.036). CONCLUSIONS: Patients with COPD have more CAD than controls and this is associated with increased dyspnoea, reduced exercise capacity and increased mortality. These data indicate that the presence of CAD in patients with COPD is associated with poor clinical outcomes.